Haverford Financial Services Inc. Acquires 4,433 Shares of Eli Lilly and Company $LLY

Haverford Financial Services Inc. grew its holdings in Eli Lilly and Company (NYSE:LLY) by 120.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,126 shares of the company’s stock after purchasing an additional 4,433 shares during the quarter. Eli Lilly and Company comprises about 1.9% of Haverford Financial Services Inc.’s investment portfolio, making the stock its 26th largest position. Haverford Financial Services Inc.’s holdings in Eli Lilly and Company were worth $6,334,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Lazard Freres Gestion S.A.S. raised its position in shares of Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after acquiring an additional 41,222 shares during the period. Precedent Wealth Partners LLC increased its stake in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares in the last quarter. Capital Advisors Inc. OK raised its holdings in Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after purchasing an additional 429 shares during the period. Family CFO Inc acquired a new stake in Eli Lilly and Company in the second quarter worth $54,000. Finally, Duquesne Family Office LLC boosted its position in shares of Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after purchasing an additional 32,640 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 0.9%

NYSE:LLY opened at $1,030.49 on Wednesday. The company has a market cap of $974.21 billion, a P/E ratio of 67.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,040.72. The business has a 50 day moving average price of $838.20 and a two-hundred day moving average price of $782.36. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the company earned $1.18 earnings per share. The firm’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Wall Street Analyst Weigh In

A number of analysts recently commented on LLY shares. HSBC upped their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Guggenheim reiterated a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. The Goldman Sachs Group increased their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. Finally, CICC Research lifted their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,020.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.